A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.
Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.
ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.
Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.
In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.